Sony DADC BioSciences and TSMC Receive AACC Award
|
By LabMedica International staff writers Posted on 29 Jul 2014 |
The American Association for Clinical Chemistry (AACC) presented Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC; Hsinchu, Taiwan) with the AACC Industry Division Award.
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
- EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time.... Read more
World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
Type 1 Diabetes (T1D) affects more than eight million people worldwide, with numbers expected to rise sharply. While most cases are genetically driven, only one in ten patients has a family history, making... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more









